Vitrolife AB (publ) becomes lead investor in AutoIVF
Vitrolife Group (VTRLY) has announced a strategic investment in AutoIVF, becoming its lead investor. AutoIVF is developing OvaReady™, an automated system that streamlines egg retrieval and preparation in IVF procedures. The technology aims to enhance fertility services and enable egg retrieval outside traditional IVF lab settings.
This investment aligns with Vitrolife's strategy to develop an end-to-end platform connecting products and services across the IVF workflow. The financial impact is described as minimal, with more details to be disclosed during Q2 earnings. The partnership aims to accelerate AutoIVF's path to market and expand access to fertility care through automation and innovation.
Vitrolife Group (VTRLY) ha annunciato un investimento strategico in AutoIVF, diventandone il principale investitore. AutoIVF sta sviluppando OvaReady™, un sistema automatizzato che ottimizza la raccolta e la preparazione degli ovociti nelle procedure di fecondazione in vitro (FIV). Questa tecnologia mira a migliorare i servizi di fertilità e a permettere la raccolta degli ovociti al di fuori dei laboratori tradizionali di FIV.
Questo investimento è in linea con la strategia di Vitrolife di creare una piattaforma integrata che collega prodotti e servizi lungo l’intero processo della FIV. L’impatto finanziario è descritto come minimo, con maggiori dettagli che saranno comunicati durante la presentazione dei risultati del secondo trimestre. La partnership punta ad accelerare l’ingresso di AutoIVF sul mercato e a estendere l’accesso alle cure per la fertilità attraverso l’automazione e l’innovazione.
Vitrolife Group (VTRLY) ha anunciado una inversión estratégica en AutoIVF, convirtiéndose en su principal inversor. AutoIVF está desarrollando OvaReady™, un sistema automatizado que optimiza la extracción y preparación de óvulos en procedimientos de fertilización in vitro (FIV). Esta tecnología busca mejorar los servicios de fertilidad y permitir la extracción de óvulos fuera de los laboratorios tradicionales de FIV.
Esta inversión se alinea con la estrategia de Vitrolife de desarrollar una plataforma integral que conecte productos y servicios a lo largo del proceso de FIV. El impacto financiero se describe como mínimo, y se proporcionarán más detalles durante los resultados del segundo trimestre. La asociación tiene como objetivo acelerar la entrada de AutoIVF al mercado y ampliar el acceso a la atención de fertilidad mediante la automatización y la innovación.
Vitrolife Group (VTRLY)가 AutoIVF에 전략적 투자를 발표하며 주요 투자자가 되었습니다. AutoIVF는 IVF 시술에서 난자 채취 및 준비 과정을 자동화하는 OvaReady™ 시스템을 개발 중입니다. 이 기술은 생식 서비스의 효율성을 높이고 전통적인 IVF 실험실 외부에서도 난자 채취가 가능하도록 하는 것을 목표로 합니다.
이번 투자는 IVF 전 과정에 걸쳐 제품과 서비스를 연결하는 통합 플랫폼 개발이라는 Vitrolife의 전략과 부합합니다. 재무적 영향은 미미하며, 2분기 실적 발표 시 추가 세부 정보가 공개될 예정입니다. 이 파트너십은 AutoIVF의 시장 진입을 가속화하고 자동화 및 혁신을 통해 생식 치료 접근성을 확대하는 데 목적이 있습니다.
Vitrolife Group (VTRLY) a annoncé un investissement stratégique dans AutoIVF, devenant son principal investisseur. AutoIVF développe OvaReady™, un système automatisé qui simplifie la collecte et la préparation des ovocytes lors des procédures de FIV. Cette technologie vise à améliorer les services de fertilité et à permettre la collecte d’ovocytes en dehors des laboratoires traditionnels de FIV.
Cet investissement s’inscrit dans la stratégie de Vitrolife de développer une plateforme complète reliant produits et services tout au long du processus de FIV. L’impact financier est qualifié de minimal, avec plus de détails qui seront communiqués lors des résultats du deuxième trimestre. Ce partenariat vise à accélérer la mise sur le marché d’AutoIVF et à étendre l’accès aux soins de fertilité grâce à l’automatisation et à l’innovation.
Vitrolife Group (VTRLY) hat eine strategische Investition in AutoIVF bekanntgegeben und ist damit Hauptinvestor geworden. AutoIVF entwickelt OvaReady™, ein automatisiertes System, das die Eizellentnahme und -vorbereitung bei IVF-Verfahren vereinfacht. Die Technologie zielt darauf ab, die Fertilitätsdienste zu verbessern und die Eizellentnahme außerhalb traditioneller IVF-Labore zu ermöglichen.
Diese Investition passt zur Strategie von Vitrolife, eine durchgängige Plattform zu entwickeln, die Produkte und Dienstleistungen im IVF-Ablauf miteinander verbindet. Die finanziellen Auswirkungen werden als gering beschrieben, weitere Details werden im Rahmen der Quartalsergebnisse im zweiten Quartal bekanntgegeben. Die Partnerschaft soll den Markteintritt von AutoIVF beschleunigen und den Zugang zur Fertilitätsversorgung durch Automatisierung und Innovation erweitern.
- Strategic investment aligns with corporate strategy to improve IVF accessibility and affordability
- Investment strengthens Vitrolife's position in automated IVF solutions
- Partnership could enable expansion of IVF services beyond traditional laboratory settings
- Financial impact described as minimal, suggesting limited near-term revenue contribution
- Early-stage investment carries inherent technology and market adoption risks
AutoIVF, is an early-stage MedTech company with the aim to make IVF more accessible, affordable and efficient. Its technology, OvaReady™, is a groundbreaking automated system that simplifies and enhances egg retrieval and preparation, enabling high-quality fertility services in the current IVF process and also supports decentralising the egg retrieval process outside traditional IVF laboratory settings.
''This investment marks another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care," says Bronwyn Brophy O'Connor, CEO of the Vitrolife Group.
Ravi Kapur, CEO of AutoIVF, shares, "With this new investment and partnership, we are excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem."
Financial impact is minimal, more details will be disclosed during the Q2 earnings release.
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
Contact:
Amelie Wilson, Investor Relations, awilson@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Vitrolife AB (publ) becomes lead investor in AutoIVF |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-becomes-lead-investor-in-autoivf-302450133.html
SOURCE Vitrolife AB
FAQ
What is the purpose of Vitrolife's (VTRLY) investment in AutoIVF?
What is AutoIVF's OvaReady™ technology?
What is the financial impact of Vitrolife's investment in AutoIVF?
How will this investment benefit Vitrolife's (VTRLY) business strategy?
